Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease.

J Clin Med · 2019 · PMC6832302 · PMID 31590290

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In a previous meta-analysis, patients with EHRA type 2 VHDs (total n = 13,585 treated with warfarin and NOAC) showed a trend for higher rates of ischemic stroke/systemic embolic events, significantly higher rates of major bleeding and all-cause death than without EHRA type 2 VHDs [ 10 ].

also in 53,322 other papers

a nonsignificant trendno p-value reported

NOAC showed a nonsignificant trend for a lower risk of ICH when compared to warfarin (HR: 0.843, 95% CI: 0.523–1.321, Figure 3 , panel A).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.